Skip to content
MarketScale
‹ Back to IndustriesHealthcare

From Data to Decisions: Leadership, Trust, and AI in Healthcare with Dr. Julia Rehman

Healthcare leaders often struggle to convert abundant data and AI investments into actionable decisions that improve care. Dr. Julia Rehman emphasizes that effective AI integration requires human judgment in the loop, strong governance frameworks, and frontline staff engagement, especially in resource-constrained settings.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

By Kevin Stevenson · Healthcare AiData GovernanceDigital TransformationClinical Leadership
Share

Key takeaways

01

AI should target specific operational challenges like staffing, readmissions, and bed capacity, with humans retaining decision-making authority.

02

Few healthcare organizations have governance structures to ensure accountability, audit trails, bias monitoring, and oversight as AI adoption accelerates.

03

Data richness without strategic insight and human judgment informed by experience limits the value of technology investments in healthcare.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Healthcare organizations today possess an unprecedented amount of data, supported by investments in artificial intelligence (AI), predictive analytics, clinical documentation tools, and sophisticated dashboards. Yet, many leaders struggle to turn this wealth of information into actionable decisions that enhance patient care, support caregivers, and improve organizational performance.

In a recent episode of "I Don’t Care" with Dr. Kevin Stevenson, internationally recognized healthcare executive Dr. Julia Rehman shared insights on health data governance, AI, and digital transformation. Drawing from her experiences across the United States, India, Saudi Arabia, and the United Arab Emirates, Dr. Rehman explored how healthcare entities can harness AI without losing sight of the fundamental human element of care.

Balancing AI with human judgment

The key to effective AI integration in healthcare, according to Dr. Rehman, is to resist treating it as a catch-all solution. Instead, leaders should focus on specific operational challenges such as staffing, readmissions, bed capacity, and patient flow, where AI can significantly aid decision-making. Dr. Rehman emphasizes that while AI can help identify patterns and provide insights, "there is a human in the loop when it comes to decision making." The technology should support, not replace, human intuition and judgment.

This is particularly crucial for rural and underserved healthcare organizations. Limited resources in these areas mean that efficiency is paramount. AI can help extend capabilities, manage risk, and streamline decision-making processes. However, Dr. Rehman cautions that these benefits cannot be realized unless frontline employees are engaged during the selection and implementation process. Without buy-in and proper training, staff may circumvent the tools, leading to ineffective outcomes and wasted investments.

The necessity of governance

As AI embeds itself deeper into healthcare operations, robust governance structures become essential. Dr. Rehman insists on critical questions such as: Who is accountable for AI tools and their decisions? What processes exist for addressing questionable outputs? How will organizations monitor for bias and performance drift, and ensure that there is a reliable audit trail? Such questions transcend technical considerations and touch upon leadership, clinical, operational, and governance responsibilities.

Dr. Rehman notes that few healthcare organizations are adequately prepared to govern AI to the extent necessary. Many are already adopting AI features in electronic health records and other tools without a comprehensive framework for oversight. This could lead to adoption outpacing accountability, with potentially adverse effects on patient safety and organizational efficacy.

From data richness to strategic insight

A prevalent issue in healthcare is not the lack of data but the challenge of converting data into strategic insights. Dr. Rehman describes many organizations as "data-rich and insight-poor," where data is often relegated to a reporting function rather than being leveraged as a strategic asset. Leaders can sometimes dismiss data as inaccurate without assigning ownership and accountability for its validity and operational relevance.

Moreover, while data can enhance decision-making, it cannot replace the need for human judgment informed by experience, organizational culture, and community understanding. As the healthcare landscape becomes increasingly driven by technology, it remains crucial to remember that the core of healthcare is fundamentally about people, not just metrics.

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Kevin Stevenson
Kevin StevensonTop Hospital Administrator & Healthcare COO, I Don't Care
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

Kevin Stevenson
Kevin Stevenson

Top Hospital Administrator & Healthcare COO

I Don't Care

DJ
Dr. Julia Rehman

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512